Alzheimer’s disease (AD) is characterized by progressive loss of cognitive abilities. Glutamate being the major excitatory neurotransmitter in mammalian brain, regulates various cognitive functions. Reports suggesting compromised cerebral glutamate homeostasis in AD indicates the potential of glutamate mapping in early diagnosis of AD. In the current study, we have used glutamate weighted Chemical Exchange Saturation Transfer (GluCEST) MRI to investigate changes in cerebral glutamate in 6-month-old APPNL-F/NL-F mouse model of AD. Our findings suggest reductions in the levels of cortical and hippocampal glutamate in APPNL-F/NL-F mice. A longitudinal study is ongoing to understand the pattern of perturbation with disease progression.
This abstract and the presentation materials are available to members only; a login is required.